Navigation Links
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Date:11/11/2009

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2009. Revenue for the third quarter of 2009 was $25,000 compared to $26,000 for the quarter ended September 30, 2008. Revenue for the nine months ended September 30, 2009 was $80,000 compared to $83,000 for the nine months ended September 30, 2008.

Dendreon's total operating expenses for the third quarter of 2009 were $25.8 million compared to $17.3 million in 2008. Dendreon's total operating expenses for the nine months ended September 30, 2009 were $63.7 million compared to $55.1 million for the same period in 2008.

The net loss for the quarter ended September 30, 2009 was $45.6 million, or $0.40 per share, compared to a net loss of $26.8 million, or $0.29 per share, for the quarter ended September 30, 2008. The net loss for the quarter ended September 30, 2009 includes a non-cash charge associated with the revaluation of warrants of $19.4 million or $0.17 per share, compared to a non-cash charge of $9.1 million or $0.10 per share, for the quarter ended September 30, 2008. The net loss for the nine months ended September 30, 2009 was $187.7 million, or $1.79 per share, compared to $62.8 million, or $0.71 per share for the nine months ended September 30, 2008. The net loss for the nine months ended September 30, 2009 includes a non-cash charge associated with the revaluation of warrants of $122.8 million or $1.17 per share, compared to a non-cash charge of $6.8 million or $0.08 per share, for the quarter ended September 30, 2008.

Cash, cash equivalents and short-term and long-term investments at September 30, 2009 totaled $259.6 million compared to $108.5 million at December 31, 2008.

Recent Highlights:

  • Submitted amendment to Biologics Li
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
5. Dendreon Reports Second Quarter 2009 Financial Results
6. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
7. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
10. Dendreon Announces Closing of Common Stock Offering
11. Dendreon Announces Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... 19 Lightwave Logic, Inc. (OTC Bulletin Board: LWLG ... on the development of electro-optic polymer materials for applications ... today the addition of Anthony J. Cocuzza, PhD to ... in medicinal chemistry and brings a highly developed set ...
... -- What do Saturn and flowers have in common? ... easily recognizable in the natural world. Now, at an ... University of Massachusetts have created a unique set of ... will consistently assemble themselves into these and other complex ...
... FOLD ) announced today that Stephen Bloch, ... from the Company,s Board of Directors effective February 17, ... Amicus, board since 2004. About Amicus Therapeutics ... oral therapeutics known as pharmacological chaperones for the treatment ...
Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Sophisticated nano-structures assembled with magnets 2Sophisticated nano-structures assembled with magnets 3
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
(Date:4/17/2014)... Pine forests are chock full of wild animals and ... populations of fungi are churning away in the soil, ... , Despite the vital role these fungi play in ... A Stanford-led team of scientists has generated a genetic ... North America. The work was published this week in ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... friend," and rightly so. Consider, for example, that they never ... us when we arrive home, and provide comfort when we ... have worked with and lived next to humans, which some ... the 400 breeds and varieties are unique, but only one ...
... use of a robot to assist with the most ... patient,s risk of developing a rare but serious complication, ... edition of the Journal of Robotic Surgery. ... School at Houston statistically analyzed operative times, length of ...
... Harbor Laboratory (CSHL) professor David Jackson, Ph.D., and a team ... development of the maize plant, commonly known in the United ... understanding of how the different parts of maize arise--important information ... in the U.S. and a mainstay of the global food ...
Cached Biology News:Lessons from the Iditarod 2Lessons from the Iditarod 3Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2Researchers find an essential gene for forming ears of corn 2
... The epitope recognized by ... of isoform 5 of human ... AAH19917.1 (GeneID 9444). The ... isoforms 1, 2, 3, 4, ...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
...
See product name for description....
Biology Products: